scholarly journals The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a ‘high-risk’ population

2019 ◽  
Author(s):  
Gabrielle McCallum ◽  
Keith Grimwood ◽  
Victor Oguoma ◽  
Amanda Leach ◽  
Heidi Smith-Vaughan ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
High Risk ◽  
Point Prevalence ◽  
High Risk Population ◽  
Northern Australia ◽  
Community Based ◽  
Risk Population ◽  
Syncytial Virus

scholarly journals Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Marcello Lanari ◽  
Silvia Vandini ◽  
Maria Grazia Capretti ◽  
Tiziana Lazzarotto ◽  
Giacomo Faldella
Keyword(s):  
Respiratory Syncytial Virus ◽  
High Risk ◽  
Primary Immunodeficiency ◽  
Respiratory Infections ◽  
Cell Immune Response ◽  
High Risk Population ◽  
Virus Infections ◽  
Inherited Disorders ◽  
Epidemic Season ◽  
Syncytial Virus

Primary immunodeficiencies are rare inherited disorders that may lead to frequent and often severe acute respiratory infections. Respiratory syncytial virus (RSV) is one of the most frequent pathogens during early infancy and the infection is more severe in immunocompromised infants than in healthy infants, as a result of impaired T- and B-cell immune response unable to efficaciously neutralize viral replication, with subsequent increased viral shedding and potentially lethal lower respiratory tract infection. Several authors have reported a severe clinical course after RSV infections in infants and children with primary and acquired immunodeficiencies. Environmental prophylaxis is essential in order to reduce the infection during the epidemic season in hospitalized immunocompromised infants. Prophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F protein, is currently recommended in high-risk infants born prematurely, with chronic lung disease or congenital heart disease. Currently however the prophylaxis is not routinely recommended in infants with primary immunodeficiency, although some authors propose the extension of prophylaxis to this high risk population.

scholarly journals Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study

2017 ◽  
Vol 6 (3) ◽  
Author(s):  
Bruno Cesar Bacchiega ◽  
Ana Beatriz Bacchiega ◽  
Magali Justina Gomez Usnayo ◽  
Ricardo Bedirian ◽  
Gurkirpal Singh ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Clinical Study ◽  
Coronary Artery ◽  
High Risk ◽  
Interleukin 6 ◽  
High Risk Population ◽  
Community Based ◽  
Risk Population ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document